Specialty leadership Global leadership in COVID-19 and respiratory trials combined with a multi-specialty Phase I-IV site network presents a compelling platform for pharma sponsors seeking fast enrollment and high-quality data in infectious disease and respiratory programs.

Regional footprint Based in Florida with multiple sites in the state, offering regional access for trial populations and the potential to expand into broader Southeast markets or targeted US regions for sponsor trials needing diverse patient cohorts.

Mid-market scale Revenue in the $10M-$25M range and a lean employee base signals agility and personalized site-level engagement, which can be positioned to sponsors as a cost-efficient alternative to larger CROs while maintaining capability for Phase I-IV studies.

Digital enablement Tech stack including Google Cloud and modern web tools supports scalable data collection and site operations; leverage to pitch streamlined data management, secure cloud-based workflows, and enhanced trial visibility for sponsors.

Growth potential Closely contrasting with larger established players, there is opportunity to propose rapid-start capabilities, competitive timelines, and focused partnerships in COVID-19 and respiratory areas, complemented by potential expansions into additional therapeutic areas and new geographic markets.